The Translational Genomics Research Institute

Translational Genomics Research Institute, doing business as Tgen Research Institute, is a Phoenix, Arizona–based nonprofit biomedical research organization that acts as a prime recipient on federal research grants and a prime contractor on small research contracts, with secondary engagement as a sub-recipient and subcontractor on larger federal research programs. The vendor delivers genomic sequencing, molecular profiling, computational analysis, and precision medicine research services across oncology, infectious disease, neurodegenerative disease, and immunology. TGen competes in full-and-open procurements and does not hold SBA set-aside certifications.

TGen's federal footprint is dominated by research grants from the National Institutes of Health, which accounts for the vast majority of its funding relationships. The top five customer agencies by award count represent 59 percent of all awards: the Department of Health and Human Services National Institutes of Health (36 awards across all institutes), the National Cancer Institute (26 awards), the National Institute on Aging (17 awards), the National Institute of Allergy and Infectious Diseases (16 awards, $6.8 million combined potential value), and the National Heart Lung and Blood Institute (11 awards). By potential value, NIAID dominates at $6.8 million across 16 awards, followed by the Department of Agriculture Animal and Plant Health Inspection Service at $5.3 million for SARS-CoV-2 surveillance work ($5.34 million definitive contract for sample collection and biosecurity assessment in wildlife rehabilitation facilities, July 2023–December 2025), the Department of Homeland Security Science and Technology Directorate at $4.3 million, and the CDC at $3.5 million across five awards. This split between award count and dollar value reflects TGen's mixed model of high-volume small research grants from NIH and fewer, larger service contracts from mission agencies.

Recent representative prime contract work includes a $6.8 million definitive contract from NIAID (awarded September 2024, completion September 2029) for mycobacterium tuberculosis proteome-wide epitope discovery and T cell phenotyping in high-disease-burden populations, a $171 thousand purchase order from the National Human Genome Research Institute (awarded September 2025, completion September 2026) for a pilot study on sex differences in early-life developmental origins of disease, and a $66 thousand purchase order from the National Institute on Aging (awarded June 2024, completion December 2024) for long-read RNA sequencing services. Grant work has included a $305,960 project grant from the National Institute of Neurological Disorders and Stroke (awarded April 2026, completion March 2028, CFDA 93.853) for molecular cartography of glioma cell initiation and infiltration patterns using spatial transcriptomics; a $1.54 million project grant from the Defense Health Agency (awarded August 2023, completion July 2027, CFDA 12.420) for genomic dissection of structural mutations in glioblastoma; and a $384 thousand project grant from the Defense Health Agency (awarded September 2025, completion August 2027, CFDA 12.420) titled "Single: Signature Enabling Glioma Enrollment."

TGen acts as a sub-recipient and subcontractor on multi-institutional research programs led by academic and health system partners, including Beckman Research Institute of the City of Hope, Cleveland Clinic, Vanderbilt University Medical Center, Yale University, University of Arizona, University of New Mexico, and Northern California Institute for Research and Education. In these roles TGen provides genomic profiling, molecular sequencing, bioinformatics, and computational analysis services. Representative sub-award work includes supporting the Beckman Research Institute on glioma tumor profiling and biospecimen coordination for oncology clinical trials; performing whole-genome sequencing and tuberculosis genomic analysis for Yale on drug-resistant TB epidemiology studies; conducting spatial transcriptomics and single-nuclei RNA sequencing for the City of Hope on preclinical glioma models; and providing extracellular vesicle RNA sequencing and analysis for the Medical College of Wisconsin on cardiac hypertrophy phenotypes. TGen also subcontracts to the University of Florida for DNA isolation, genotyping, and data analysis on neurological disease cohorts and to Arizona State University on Alzheimer's disease research and cognitive health studies.

Activity has grown from 12 awards in 2022 to a peak of 25 in 2024, with recent moderation to 18 in 2025 and nine in 2026 year-to-date. Only eight awards face ultimate completion in the next twenty-four months (combined potential value $171 thousand), representing minimal recompete pressure. TGen's principal NAICS categories are Testing Laboratories and Services (6 awards) and Research and Development in Biotechnology (5 awards). The vendor maintains a named subsidiary, Precision Medicine Facilities LLC, a nonprofit limited liability company. The obligated dollar volume across all awards ($350.8 million) significantly exceeds the combined potential ceiling ($23.1 million), indicating substantial historical drawdown against grant and contract awards dating to 2001 and reflecting the vendor's mature, established position as a federally funded research organization serving NIH and broader health agencies through both discovery research and applied genomic service delivery.